Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

  • Awaiting development
  • GID-TA11538
  • Expected publication date: TBC
Please note that ID6428 is a new combined topic ID that covers ID6206 and ID6146.